GDC 0810

Drug Profile

GDC 0810

Alternative Names: ARN 810; GDC-0810; RG 6046; RO-7056118

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Aragon Pharmaceuticals
  • Developer Genentech
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Selective estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer

Most Recent Events

  • 01 Jun 2016 Genentech completes a phase I pharmacokinetics trial in Healthy volunteers in USA (PO, Liquid) (NCT02802670)
  • 01 May 2016 Phase-I clinical trials in Breast cancer (In volunteers) in USA (PO, Liquid) (NCT02802670)
  • 31 Mar 2016 Genentech plans a phase I pharmacokinetics trial in Healthy volunteers in United Kingdom (NCT02722018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top